A phase I/II radioimmunotherapy study using B-B4 conjugated to iodine-131 was conducted in refractory multiple myeloma patients [143] and significantly improved clinical outcome than the control group, suggesting that targeted radioimmunotherapy is feasible using an anti-SDC1 monoclonal antibody [143]. The gene discussed is SDC1; the disease is AL amyloidosis.